jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni
Company profile
Ticker
JAZZ
Exchange
Website
CEO
Bruce Cozadd
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
JAZZ PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Jazz Pharmaceuticals Ireland Limited • GW Pharma Limited • Jazz Pharmaceuticals, Inc. • Celator Pharmaceuticals Inc. • Jazz Pharmaceuticals Research UK Limited • Gentium S.r.l. • Jazz Pharmaceuticals UK Holdings Limited • Jazz Financing Holdings Limited • Jazz Pharmaceuticals International Limited • Jazz Investments Europe Limited ...
IRS number
981032470
JAZZ stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
28 Feb 24
8-K
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results
28 Feb 24
8-K
Departure of Directors or Certain Officers
27 Feb 24
8-K
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
21 Feb 24
8-K
Entry into a Material Definitive Agreement
25 Jan 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Departure of Directors or Certain Officers
15 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
8 Nov 23
8-K
Departure of Directors or Certain Officers
12 Sep 23
Transcripts
JAZZ
Earnings call transcript
2023 Q4
28 Feb 24
JAZZ
Earnings call transcript
2023 Q3
8 Nov 23
JAZZ
Earnings call transcript
2023 Q2
9 Aug 23
JAZZ
Earnings call transcript
2023 Q1
10 May 23
JAZZ
Earnings call transcript
2022 Q4
1 Mar 23
JAZZ
Earnings call transcript
2022 Q3
10 Nov 22
JAZZ
Earnings call transcript
2022 Q2
3 Aug 22
JAZZ
Earnings call transcript
2022 Q1
5 May 22
JAZZ
Earnings call transcript
2021 Q4
2 Mar 22
JAZZ
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
87.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 474 |
Opened positions | 63 |
Closed positions | 46 |
Increased positions | 155 |
Reduced positions | 177 |
13F shares | Current |
---|---|
Total value | 7.14 tn |
Total shares | 55.27 mm |
Total puts | 94.80 k |
Total calls | 134.42 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 7.19 mm | $930.27 bn |
Vanguard | 6.38 mm | $825.70 bn |
LSV Asset Management | 2.37 mm | $306.58 bn |
STT State Street | 2.33 mm | $300.95 bn |
Wellington Management | 1.67 mm | $215.97 bn |
JPM JPMorgan Chase & Co. | 1.43 mm | $184.59 bn |
Samlyn Capital | 1.36 mm | $175.89 bn |
FMR | 1.33 mm | $172.56 bn |
Renaissance Technologies | 1.31 mm | $169.00 bn |
AMP Ameriprise Financial | 1.30 mm | $168.22 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Gala Renee D | Ordinary Shares | Payment of exercise | Dispose F | No | No | 115.21 | 1,736 | 200.00 k | 55,357 |
7 Mar 24 | Patricia Carr | Ordinary Shares | Sell | Dispose S | No | No | 116.98 | 1,768 | 206.82 k | 6,596 |
6 Mar 24 | Patricia Carr | Ordinary Shares | Sell | Dispose S | No | No | 117.51 | 700 | 82.26 k | 8,364 |
6 Mar 24 | Patricia Carr | Ordinary Shares | Sell | Dispose S | No | No | 120.85 | 1,236 | 149.37 k | 9,064 |
5 Mar 24 | Bruce C Cozadd | Ordinary Shares | Payment of exercise | Dispose F | No | No | 117.53 | 22,436 | 2.64 mm | 429,809 |
5 Mar 24 | Neena M Patil | Ordinary Shares | Payment of exercise | Dispose F | No | No | 117.53 | 3,432 | 403.36 k | 41,629 |
5 Mar 24 | Robert Iannone | Ordinary Shares | Payment of exercise | Dispose F | No | No | 117.53 | 4,294 | 504.67 k | 62,226 |
News
Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
10 Apr 24
Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $180 Price Target
10 Apr 24
How To Make Your Cannabis Business More Attractive For Investors In 2024: Advice On Financial Health & Innovation
25 Mar 24
Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $180 Price Target
22 Mar 24
Truist Securities Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target
20 Mar 24
Press releases
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
10 Apr 24
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
2 Apr 24
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
12 Mar 24
Agrify Corp Stock Presents Compelling Opportunity As Deal Flow Intensifies ($AGFY)
7 Mar 24
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
27 Feb 24